Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC

Exclusion Criteria

• •Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; the total dose of cisplatin should be less than 300mg/m\^2).
• •Patients with active (significant or uncontrolled) gastrointestinal bleeding.
• •Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity ≥ grade 2 NCI-CTCAE 4.0.
• •Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.
• •History of documented congestive heart failure; angina pectoris requiring medication;evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP \> 180 mmHg or diastolic BP \> 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.
• •Baseline left ventricular ejection fraction (LVEF) \< 50% (measured by echocardiography or MUGA).
• •Patients with dyspnoea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.
• •Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed).
• •Clinically significant hearing abnormality.
• •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
• •History or clinical evidence of brain metastases.
• •Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.
• •Positive serum pregnancy test in women of childbearing potential.
• •Received any investigational drug treatment within 4 weeks of start of study treatment.
• •Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastatic site peripherally and patient recovered from any acute toxicity;prior adjuvant radiotherapy is allowed if complete at least 6 months ).
• •Major surgery within 4 weeks of start of study treatment, without complete recovery.
• •Patients with known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).
• •Known hypersensitivity to any of the study drugs.